C2C Stock Chart & Stats
€6.25
€0.00(0.00%)
At close: 4:00 PM EST
€6.25
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€6.05 - €6.25
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€14.61M
Enterprise Value€3.34B
Total Cash (Recent Filing)€297.79M
Total Debt (Recent Filing)€3.63B
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,815,458
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)>-0.01
Price to Sales (P/S)0.00853
P/FCF Ratio-0.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe 2025 revenue rebound indicates renewed demand for CCM’s oncology-focused clinical, radiotherapy, and diagnostic imaging services. If this recovery persists, higher patient volumes and equipment utilization could improve operating leverage and strengthen the company’s platform over the next several quarters.
Improving Losses And Cash BurnAlthough CCM remains loss-making and cash-flow negative, the substantial improvement from 2024 suggests that financial deterioration has moderated. Continued progress in losses and cash usage would preserve more resources for oncology operations and reduce the pace at which external financing is required.
Management ContinuityThe appointment of an interim CFO with extensive tenure across Concord Medical and its subsidiary supports continuity in financial oversight during the leadership transition. That familiarity may help maintain execution across the group’s oncology-focused healthcare operations and reduce disruption.
Bears Say
Persistent Operating LossesRecurring operating and net losses show that CCM has not yet demonstrated a durable, self-sustaining earnings model. This can restrict reinvestment in oncology capabilities, limit financial resilience, and make future performance dependent on continued operational improvement rather than established profitability.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow indicate that the core business is still consuming cash rather than funding its own needs. This weakens flexibility to maintain equipment and expand services, while increasing reliance on financing or other external sources of liquidity.
High Leverage And Negative EquityThe combination of substantial debt and deeply negative equity leaves CCM with a materially imbalanced capital structure. High leverage can constrain investment in oncology services, increase financing risk, and reduce the company’s ability to absorb further losses or operating setbacks.
Concord Medical Services News
C2C FAQ
What was Concord Medical Services’s price range in the past 12 months?
Concord Medical Services lowest stock price was €6.05 and its highest was €6.25 in the past 12 months.
What is Concord Medical Services’s market cap?
Concord Medical Services’s market cap is €14.61M.
When is Concord Medical Services’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Concord Medical Services’s earnings last quarter?
Currently, no data Available
Is Concord Medical Services overvalued?
According to Wall Street analysts Concord Medical Services’s price is currently Overvalued.
Does Concord Medical Services pay dividends?
Concord Medical Services does not currently pay dividends.
What is Concord Medical Services’s EPS estimate?
Concord Medical Services’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Concord Medical Services have?
Concord Medical Services has 2,815,458 shares outstanding.
What happened to Concord Medical Services’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Concord Medical Services?
Currently, no hedge funds are holding shares in DE:C2C
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Concord Medical Services
Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People’s Republic of China. It operates in two segments, Network and Hospital. The company’s services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, China.
Technical Analysis
American Shared Hospital Services
―
Joint
―
Cryo-Cell International
―
DocGo
―
P3 Health Partners
―